ArticleCureus2025
Exploring Adipokines in Assessing the Role of Dehydroepiandrosterone in Polycystic Ovary Syndrome-Linked Infertility.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolycystic ovary syndrome (PCOS) is an endocrine condition that affects women and results in imbalance prevalence, as well as infertility in most cases. Adipose tissue hormones, such as adiponectin and leptin, participate in metabolism and may influence the maturation of reproductive hormones. Dehydroepiandrosterone (DHEA) is a natural steroid that performs several functions, including fertility-enhancing effects. This can be attributed to the fact that it regulates hormones.
objectiveThe objective of this research article is to note the effects that DHEA supplementation caused on reproductive hormones and adipokines in infertile women suffering from PCOS. METHODOLOGY: A sample of 60 infertile women with PCOS desiring children was distributed into study groups, and the groups were classified at random and did not vary in terms of size. The researchers assigned Group A a 75 mg per day oral supplement of DHEA within 12 weeks, whereas Group B received no supplement at all. The hormones anti-Müllerian hormone (AMH), luteinizing hormone (LH), and estradiol (E2) were measured at baseline and at the end of the 12-week period. The level of leptin and adiponectin was also determined.
resultsThe 12-week DHEA treatment resulted in increased AMH and estradiol levels when compared to the control group. Moreover, individuals within the DHEA group exhibited an increasing adiponectin level and a decreasing leptin level, which is a prediction of better metabolic efficiency.
conclusionThe effect of DHEA on reproductive hormones and adipokine levels could be positive in women who have such benefits regarding infertility. The researchers conclude that the outcome of the study indicates that when these individuals are provided with DHEA, it enhances the probability of having a child. Nonetheless, it is essential to continue examining its safety and effectiveness over an extended period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.